Brief: Vistagen Therapeutics - On March 7, Received Letter From Nasdaq That Co Granted Until Sept 5, 2023 To Regain Compliance With Min Bid Price Requirement
07/03/2023 21:49
March 7 (Reuters) - VistaGen Therapeutics Inc VTGN.O :
* VISTAGEN THERAPEUTICS - ON MARCH 7, RECEIVED LETTER FROM
NASDAQ
THAT CO GRANTED UNTIL SEPT 5, 2023 TO REGAIN COMPLIANCE WITH MIN
BID PRICE REQUIREMENT
Further company coverage: VTGN.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Vistagen Therapeutics
See all newsBrief: Vistagen TherapeuticsSays Fasedienol Nasal Spray Well-Tolerated With No New Drug-Related Safety Findings After 12 Months
VistaGen Q1 revenue rises on licensing agreement expiration
Brief: VistaGen Q1 EPS USD -0.3
Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Vistagen Appoints Douglas J. Williamson To Its Board Of Directors